Search company, investor...

Antisense Pharma

antisense-pharma.com

Founded Year

1998

Stage

Series A | Alive

Total Raised

$11.6M

Last Raised

$11.6M | 11 yrs ago

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company committed to researching, developing and marketing drugs that enable targeted treatment of aggressive tumor diseases. The company's main objective is to extend the life expectancy of patients considerably and, at the same time, improve quality of life.

Headquarters Location

Josef-Engert-Strasse 9

93053,

Germany

Missing: Antisense Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Antisense Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Antisense Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Antisense Pharma is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Antisense Pharma Patents

Antisense Pharma has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/10/2011

1/20/2015

Molecular biology, Drug delivery devices, Biotechnology, Dosage forms, Proteins

Grant

Application Date

6/10/2011

Grant Date

1/20/2015

Title

Related Topics

Molecular biology, Drug delivery devices, Biotechnology, Dosage forms, Proteins

Status

Grant

Latest Antisense Pharma News

Germany’s Antisense Pharma Closes On About $11M In Financing

Jul 6, 2011

Germany’s Antisense Pharma Closes On About $11M In Financing July 6, 2011 By Mark Boslet Antisense Pharma said Wednesday that MIG Funds 2, 3 and 9 as well as GAF have ponied up a new round of financing worth about $11 million, or about 8 million euros. The German bio-pharmaceutical startup also said its founder and chief executive, Karl-Hermann Schlingensiepen, will leave his operational role and join the supervisory board, in addition to focus on strategy as a consultant PRESS RELEASE Antisense Pharma completes round of financing worth approximately 8 million euro – Founding shareholders facilitate the participation of new investors Effective July, 2011, Antisense Pharma’s founder and CEO, Dr. Karl-Hermann Schlingensiepen, will now be a member of the supervisory board and will focus on the company’s strategy as a consultant. The biopharmaceuticalcompany Antisense Pharma announced today that MIG Funds 2, 3 and 9 as well as GAF have increased their share capital by approximately 8 million euro. In addition, the current Chief Execute Officer (CEO), Dr. Karl-Hermann Schlingensiepen changed from the operative management of Antisense Pharma to a strategic advisory position closely associated with the company as of July 1. Dr. Karl-Hermann Schlingensiepen and the investors developed this solution together. Pivotal phase II/III study on pancreatic cancer: Start of a second international clinical trial of Antisense Pharma in preparation “With this major entry into the systemic, intravenous application in solid tumors, we share Antisense Pharma’s hope that trabedersen could become the first medication approved for second-line therapy of pancreatic cancer,” says Michael Motschmann, Chief Executive of MIG Verwaltungs AG. “Trabedersen could give new hope to patients suffering from this extremely aggressive type of cancer and open up a greatly needed but thus far completely vacant market niche along with its corresponding high revenue potential. At the same time, this means a risk reduction for the development of trabedersen, as this medication now has several marketing opportunities if the trials are successful. Furthermore, there is a potential for added value since new markets can be opened up.” © 2015 Buyouts Insider / Argosy Group LLC

Antisense Pharma Frequently Asked Questions (FAQ)

  • When was Antisense Pharma founded?

    Antisense Pharma was founded in 1998.

  • What is Antisense Pharma's latest funding round?

    Antisense Pharma's latest funding round is Series A.

  • How much did Antisense Pharma raise?

    Antisense Pharma raised a total of $11.6M.

  • Who are the investors of Antisense Pharma?

    Investors of Antisense Pharma include MIG Verwaltungs, Global Asset Fund, Alfred Wieder, Global Chance Fund, S-REFIT Regionaler Finanzierungsfonds fur Innovationen und Technologieunternehmen and 6 more.

  • Who are Antisense Pharma's competitors?

    Competitors of Antisense Pharma include Nora Pharma, Zealand Pharma, Tubilux Pharma, Esperance Pharmaceuticals, Actinobac Biomed and 11 more.

Compare Antisense Pharma to Competitors

P
Photothera

Photothere is developing a therapy called NeuroThera, for the treatment of ischemic stroke.

T
TRF Pharma

TRF Pharma is a hematology and oncology focused company, developing therapies to treat diseases of abberrant cell adhesion to endothelial (blood vessel) walls. Its programs in sickle cell disease and cancer metastasis are based on heparin derivatives and heparinoid drugs.

A
Apoptos

Apoptos, Inc. is focused on discovering and developing effective, targeted small-molecule anticancer drugs that activate apoptosis (programmed cell death).

T
Tubilux Pharma

Tubilux Pharma develops, manufactures and markets pharmaceutical products.

P
PNP Therapeutics

PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.

C
CytImmune Sciences

CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.